Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Poxel
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.

At the end of 2019, the group had a portfolio of 3 products in clinical development, including 1 in Phase III (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 3 in phase II (PXL770, PXL065 and PXL007 for the treatment of glucose and lipid irregularities), and and of a product in the preclinical development phase.
Sales per Business
20182019Delta
EUR (in Million)%EUR (in Million)%
Innovating Molecules74.61100%26.56100% -64.4%
Sales per region
20182019Delta
EUR (in Million)%EUR (in Million)%
France74.61100%26.56100% -64.4%
Managers
NameAgeSinceTitle
Thomas Kuhn452009Chief Executive Officer & Director
Pierre Legault592016Chairman
Sebastien Bolze, Dr.--Chief Operating Officer & Executive Vice President
Anne Renevot--Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec, Dr.-2009Senior Vice President-Research & Development
Takashi Kaneko, Dr.--Senior Vice President-Medical
David E. Moller, Dr.--Chief Scientific Officer & Executive VP
Mohammed Khoso Baluch612013Independent Director
Richard N. Kender632015Independent Director
Pascale Boissel532015Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,471,523 21,444,454 75.3% 0 0.0% 75.3%
Shareholders
NameEquities%
Andera Partners SCA 4,061,527 14.3%
BPIFrance Investissement SAS 2,175,573 7.65%
Bpifrance Participations SA /PRIVATE EQUITY/ 2,055,721 7.23%
Thomas Kuhn 1,505,965 5.29%
Roivant Sciences Ltd. 1,430,406 5.03%
Deuterx LLC 1,289,711 4.53%
Federated Global Investment Management Corp. 664,641 2.34%
Etoile Gestion SA 97,642 0.34%
Mandarine Gestion SA 89,000 0.31%
La Banque Postale Asset Management SA 61,029 0.21%
Holdings
NameEquities%Valuation
Poxel (POXEL) 39,0820.14%314,849 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
-
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  POXEL:FR
- Reuters Code :  POXEL.PA
- Datastream Code :  
Company contact information
Poxel
Immeuble Le Sunway 259/261 Avenue Jean Jaurès
FR-69007 Lyon


Phone : +33 (0)4 37 37 20 10
Fax : +33 (0)4 37 70 88 15
Internet : http://www.poxel.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Poxel
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
POXEL-47.87%214
GILEAD SCIENCES, INC.-6.82%75 913
REGENERON PHARMACEUTICALS53.57%60 679
VERTEX PHARMACEUTICALS-2.01%55 881
WUXI APPTEC CO., LTD.63.88%39 185
BEIGENE, LTD.80.92%27 179
GENMAB A/S52.55%23 468
BIONTECH SE178.48%22 472
HUALAN BIOLOGICAL ENGINEERING INC.111.33%15 614
ARGENX SE55.29%12 488
MYOKARDIA, INC.205.21%11 862
SAREPTA THERAPEUTICS, INC.6.56%10 794
NEUROCRINE BIOSCIENCES, INC.-7.90%9 232
MIRATI THERAPEUTICS, INC.46.70%8 420
ASCENDIS PHARMA A/S12.13%8 300
BIOCON LIMITED49.74%7 093
EXELIXIS, INC.26.39%6 881
ACCELERON PHARMA INC.111.37%6 713
PEPTIDREAM INC.-12.86%5 811
ARROWHEAD PHARMACEUTICALS, INC.-13.70%5 599
ULTRAGENYX PHARMACEUTICAL INC.110.72%5 453